US › Healthcare

LENZ Therapeutics Inc (LENZ)

US · Healthcare · Biotechnology

$4.13-0.24%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$5.5M

Revenue YoY

+9.7%

Net profit

$-31.9M

EPS

$-1.02

EPS estimate

$-1.21

Net margin

-581.8%

EPS came in at -1.02 against a street estimate of -1.21 — a beat of 15.7%.

Key statistics

Market cap

$142.0M

Forward P/E

0.0

P/B

0.67

Book value

$6.98

EPS (TTM)

$-3.97

52-week high

$50.40

52-week low

$4.50

50-day MA

$5.24

200-day MA

$11.17

Beta

1.63

Analyst view

Analysts rate LENZ Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $24.00.

Shareholding

Insiders

2.65%

Institutions

111.71%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	13.30%
Alpha Wave Global LP	11.50%
FMR Inc	11.45%
Versant Venture Management LLC	8.46%
BlackRock Inc	6.29%
Aberdeen Group PLC	4.93%
Millennium Management LLC	4.80%
Squarepoint Ops LLC	4.79%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for LENZ Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.